“Prize4Life is delighted to welcome such an accomplished and talented scientific mind,” said Avi Kremer, co-founder and Chief Executive Officer of Prize4Life. “Roger Kornberg is an excellent addition to our Scientific Advisory Board."
Cambridge, MA (PRWEB) March 21, 2012
Prize4Life, a non-profit organization dedicated to accelerating the discovery of treatments and a cure for Amyotrophic Lateral Sclerosis (ALS), is pleased to announce the appointment of Roger D. Kornberg, PhD, to its Scientific Advisory Board.
“Prize4Life is delighted to welcome such an accomplished and talented scientific mind,” said Avi Kremer, co-founder and Chief Executive Officer of Prize4Life. “Roger Kornberg is an excellent addition to our Scientific Advisory Board, which provides a high level of expert knowledge and wise counsel to Prize4Life and is integral to the success of our important mission.”
Roger Kornberg is an award-winning biochemist whose pioneering research has led to several fundamental discoveries in the fields of gene transcription, regulation, and expression. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry for his seminal studies of the molecular basis of eukaryotic transcription, a milestone discovery in genetics.
Dr. Kornberg is currently a professor of structural biology at Stanford University School of Medicine, where his lab has continued to elucidate the complex process by which DNA is unraveled, read, and “transcribed” into RNA. Although his research is not directly related to ALS, Dr. Kornberg believes “Prize4Life’s mission of finding treatments and a cure for ALS is imperative. I look forward to joining the organization’s impressive assembly of scientific advisors. Through its innovative model, Prize4Life can produce real results for ALS patients.”
Prize4Life is a nonprofit organization dedicated to accelerating the discovery of treatments and a cure for ALS by using powerful incentives to attract new people and drive innovation. Prize4Life was founded in 2006 by Avi Kremer, who was diagnosed with ALS at the age of 29 while attending Harvard Business School. The organization aims to use prizes to bring new minds and new money into the fight against ALS and focus efforts on specific outcomes that will bridge the gap between academic research and the development of treatments and a cure.